GlobalData on MSN6d
EC approves CSL’s Andembry to stop hereditary angioedema attacks
CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...
PMLiVE6d
EC approves CSL’s Andembry to prevent hereditary angioedema attacks
The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...
pharmaphorum6d
EU approves CSL's once-monthly HAE drug Andembry
CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...
Stockhead on MSN3d
Dr Boreham’s Crucible: What’s all the fuss about biotech behemoth CSL?
While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...
FiercePharma16h
Regulatory tracker: Merck's Welireg wins 2 European approvals
Last month, regulators in Australia and the U.K. signed off on the medicine. "Andembry, CSL's first approved recombinant monoclonal antibody discovered and developed entirely by CSL, underscores ...
pharmaphorum2d
Intellia trumpets CRISPR drug data, but shares fall
Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its ...
PipelineReview.com6d
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
ZUG, Switzerland I February 14, 2025 I Galderma (SWX:GALD) today announced that the European Commission has approved Nemluviofor both moderate-to-severe atopic dermatitis and prurigo nodularis in the ...